LA JOLLA, Calif., Oct. 1 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it held a successful End-of-Phase II meeting for tezampanel with the U.S. Food and Drug Administration (FDA) on September 29, 2008. Based on a review of the Phase II data, the FDA agreed that TorreyPines may initiate a Phase III program for tezampanel in acute migraine. The FDA also confirmed that the required thorough QT/QTc study for tezampanel can be conducted in parallel with the first Phase III pivotal trial. The timing for initiation of a Phase III trial is dependent on the company securing a development partner or funding for the program.
The FDA meeting follows the successful completion of a 306-patient, Phase IIb acute migraine trial that demonstrated a single 40 mg dose of tezampanel was safe, well-tolerated and effective in relieving headache pain at two hours post-dose. The Phase III clinical trial design for tezampanel will evaluate the 40 mg dose as well as a lower dose, consistent with the FDA recommendation that the lowest effective dose should be identified in the development of investigational drugs.
"We are pleased with the outcome of our meeting with the FDA and their go-ahead for a Phase III program," said Ev Graham, acting chief executive officer of TorreyPines. "This successful milestone, the first in a series of clinical milestones we expect to meet this year, should significantly help us achieve our strategy of securing a corporate partner or other funding to continue development of tezampanel. We are also on track to report by the end of the year, data from our ongoing Phase I study of NGX426, the oral prodrug of tezampanel, in a capsaicin model of hyperalgesia, as well as a Phase II study of NGX267, our muscarinic agonist, in xerostomia secondary to Sjogren's syndrome."
About Tezampanel and NGX426
Tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain, including migraine. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy.
About TorreyPines Therapeutics
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.
Such forward-looking statements include, but are not limited to, statements
regarding the timing for initiating a Phase III program for tezampanel in
acute migraine, the potential for tezampanel and NGX426 as treatments for
acute migraine and other indications, the potential for NGX426 to be
analgesic, the anticipated timing of results for the NGX426 study in a
model of capsaicin-induced pain, the potential for NGX267 as a treatment
for xerostomia secondary to Sjogren's syndrome, the anticipated timing of
results from the study of NGX267 as a treatment for xerostomia secondary to
Sjogren's syndrome, and the ability to partner any of the company's product
candidates or programs. Such statements are subject to numerous known and
unknown risks, uncertainties and other factors, which may cause
TorreyPines' actual results to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements, including whether any preclinical studies or clinical trials,
either ongoing or conducted in the future, will prove successful, and if
successful, whether the results can be replicated; whether safety and
efficacy profiles of any of the company's product candidates will be
established, or if established, will remain the same, be better or worse in
future clinical trials, if any; whether pre-clinical results will be
substantiated by ongoing or future clinical trials, if any, or whether any
of the company's product candidates will be able to improve the signs or
symptoms of their respective clinical indication; whether any of the
company's product candidates will support a filing for marketing approval,
will be approved by the regulatory authorities, or if approved, will prove
competitive in the market; or whether the necessary financing to support
the company's product development programs will be available. In particular
there is no guarantee that clinical trials of any of the company's product
candidates will be completed on schedule or that results of these clinical
trials will be reported within the anticipated timeframe, that tezampanel
or NGX426 will successfully treat migraine and/or other indications for
which they are developed, that NGX267 will successfully treat xerostomia
secondary to Sjogren's syndrome, that TorreyPines will be able to complete
the necessary development work and receive regulatory approval for
tezampanel, NGX426 or NGX267 or that TorreyPines will be able to reach
agreement with a partner for any of the product candidates or programs on
terms that are acceptable to TorreyPines. These and other risks which may
cause results to differ are described in greater detail in the "Risk
Factors" section of TorreyPines' annual report on Form 10-K for the year
ended December 31, 2007 and TorreyPines other SEC reports. The
forward-looking statements are based on current information that is likely
to change and speak only as of the date hereof.
TorreyPines Therapeutics, Inc.
Russo Partners, LLC
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved